Comments on: TDI Episode 49: Pharma Huckman’s Market http://www.thedisciplinedinvestor.com/blog/2008/03/23/tdi-episode-49-pharma-huckmans-market/ Investment Disciplines and Timely Advice. Fri, 10 Feb 2012 21:15:03 +0000 hourly 1 http://wordpress.org/?v=3.3.1 By: Tony F http://www.thedisciplinedinvestor.com/blog/2008/03/23/tdi-episode-49-pharma-huckmans-market/comment-page-1/#comment-2212 Tony F Mon, 24 Mar 2008 21:23:27 +0000 http://www.thedisciplinedinvestor.com/blog/2008/03/23/tdi-episode-49-pharma-huckmans-market/#comment-2212 Mike and for those reading on the Provenge debacle who are not up-to-speed about alleged Conflict of Interests attributed to the veneral Dr. Howard Isadore Scher of Sloan-Kettering in NYC--the same person who sat in judgment at the Provenge FDA Advisory Committee meeting almost exactly a year ago... here's what's been found on the internet. Remember, Scher attested to the FDA in writing that he had but 3 COI... 1 stock and 2 competing company interests.... and, pay particular attention to items #1 and #17!!!!! # Those 17 Conflicts of Interest for Dr. Howard Isadore Scher found on the internet are: [NOTE particularly items #1 and #17] 1. NOVACEA: grants & research support; STUDY CHAIR of DN-101; …. and DIRECT COMPETITOR to Provenge 2. GPB BIOTECH: financial conflict of interest per Scher in MedPage 3. PHARMION: financial conflict of interest per Scher in MedPage 4. SANOFI-AVENTIS: grants & research support 5. BRISTOL MYERSSQUIBB: consultant, grants & research 6. MILLENNIUM PHARMCEUTICALS: grant of research support 7. COUGAR BIOTECHNOLOGY: principal investigator; advisoryboard; 8. INNOVIVE PHARMACEUTICALS: principal investigator 9. INFINITY PHARMACEUTICALS: principal investigator 10. BIOGEN-IDEC: jointly held stock with spouse 11. PFIZER: jointly held stock with spouse 12. GENTA: scientific advisory board (as of March 6, 2007; since removed from web but cached) 13. CONFOMA THERAPEUTICS: scientific advisory board 14. DEPARTMENT of DEFENSE: Principal Investigator PCClinical Trials-P1 and P2 15. AMBRILIABIOPHARMA INC: Principal Investigator PCK3145, Phase I/II 16. MEDIVATION, INC: principal investigator MDV3100 17. PROQUEST INVESTMENTS, Board of Directors, Advisor. Invested in Novacea. Mike and for those reading on the Provenge debacle who are not up-to-speed about alleged Conflict of Interests attributed to the veneral Dr. Howard Isadore Scher of Sloan-Kettering in NYC–the same person who sat in judgment at the Provenge FDA Advisory Committee meeting almost exactly a year ago… here’s what’s been found on the internet.

Remember, Scher attested to the FDA in writing that he had but 3 COI… 1 stock and 2 competing company interests…. and, pay particular attention to items #1 and #17!!!!!

#

Those 17 Conflicts of Interest for Dr. Howard Isadore Scher found on the internet are:

[NOTE particularly items #1 and #17]

1. NOVACEA: grants & research support; STUDY CHAIR of DN-101;

…. and DIRECT COMPETITOR to Provenge

2. GPB BIOTECH: financial conflict of interest per Scher in MedPage

3. PHARMION: financial conflict of interest per Scher in MedPage

4. SANOFI-AVENTIS: grants & research support

5. BRISTOL MYERSSQUIBB: consultant, grants & research

6. MILLENNIUM PHARMCEUTICALS: grant of research support

7. COUGAR BIOTECHNOLOGY: principal investigator; advisoryboard;

8. INNOVIVE PHARMACEUTICALS: principal investigator

9. INFINITY PHARMACEUTICALS: principal investigator

10. BIOGEN-IDEC: jointly held stock with spouse

11. PFIZER: jointly held stock with spouse

12. GENTA: scientific advisory board (as of March 6, 2007; since removed from web but
cached)

13. CONFOMA THERAPEUTICS: scientific advisory board

14. DEPARTMENT of DEFENSE: Principal Investigator PCClinical Trials-P1 and P2

15. AMBRILIABIOPHARMA INC: Principal Investigator PCK3145, Phase I/II

16. MEDIVATION, INC: principal investigator MDV3100

17. PROQUEST INVESTMENTS, Board of Directors, Advisor. Invested in Novacea.

]]> By: Christian http://www.thedisciplinedinvestor.com/blog/2008/03/23/tdi-episode-49-pharma-huckmans-market/comment-page-1/#comment-2210 Christian Mon, 24 Mar 2008 16:09:42 +0000 http://www.thedisciplinedinvestor.com/blog/2008/03/23/tdi-episode-49-pharma-huckmans-market/#comment-2210 Perhaps you could look into the COI's of Dr.'s Maha and Scher, a we bit more. Maybe you could let us know what happened w/ Dr. Scher's Novacea trials in regards to Asentar. I believe it was canceled because of a high rate of deaths. I enjoyed your interview w/ Mr. Huckman. Perhaps a little more insight into frequency of the FDA rejecting its own panel. Especially when the votes are 17-0 and 13-4. I look forward to your follow up story w/regards to Provenge. Perhaps you could look into the COI’s of Dr.’s Maha and Scher, a we bit more. Maybe you could let us know what happened w/ Dr. Scher’s Novacea trials in regards to Asentar. I believe it was canceled because of a high rate of deaths. I enjoyed your interview w/ Mr. Huckman. Perhaps a little more insight into frequency of the FDA rejecting its own panel. Especially when the votes are 17-0 and 13-4. I look forward to your follow up story w/regards to Provenge.

]]> By: TDI Episode 49: Pharma Huckman’s Market | Pharma Night Fever http://www.thedisciplinedinvestor.com/blog/2008/03/23/tdi-episode-49-pharma-huckmans-market/comment-page-1/#comment-2204 TDI Episode 49: Pharma Huckman’s Market | Pharma Night Fever Sun, 23 Mar 2008 20:29:23 +0000 http://www.thedisciplinedinvestor.com/blog/2008/03/23/tdi-episode-49-pharma-huckmans-market/#comment-2204 [...] Read the rest of this great post here [...] [...] Read the rest of this great post here [...]

]]>